Albumedix Ltd
Albumedix - Dedicated to Better Health
Albumedix is a science-driven, life-science company focused on enabling the creation of advanced therapies and biopharmaceuticals utilizing our high quality recombinant human albumin products and technologies. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical and medical device companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started more than 35 years ago. Our vision is to empower excellence in how we as a business operate and create products and services of the highest quality; but also to enable our customers and partners to excel in the development of transformative therapies, and thereby support life sciences and patients equally. As an example, we are proud to be working with domestic, national and international life science companies in these challenging times towards the urgent response against covid-19 - be it diagnostically, therapeutically and prophylactically.Contact Albumedix via their website
News Archive
24/06/2021 Albumedix extends research collaboration with Cobra Biologics...more
02/02/2021 Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult...more
24/11/2020 Albumedix CEO Reflects on Bio Integrates 2020...more
18/11/2020 Albumedix CEO contributes to PharmaVOICE 2021 Year in Preview...more
01/08/2018 Albumedix announces evaluation agreement with Novartis...more
26/06/2018 iNANO & Albumedix announce strategic research collaboration for Albumin carrier...more
17/10/2017 Albumedix Establishes Scientific Advisory Board...more
02/10/2017 Albumedix signs agreement with Oslo University Hospital and University of Oslo...more
17/05/2017 Albumedix will host a webinar titled: When Standard Formulation Strategies Fail...more
04/01/2017 Albumedix CEO will present a corporate overview at J.P. Morgan conference...more
04/01/2017 Albumedix Appoints Chief Medical Officer...more
19/12/2016 Nature Communications: Albumedix and collaborators publish new data...more
06/12/2016 Albumedix research agreement with New York University School of Medicine...more
17/05/2016 Albumedix Agreement with Hebei Changshan Biochem Pharma for Diabetes Treatment...more
12/05/2016 Albumedix™ Proprietary VELTIS® Drug Delivery Technology Approved In The EU...more
15/03/2016 Albumedix Technology used by CSL Behring for Haemophilia B in the US ...more
16/02/2016 Albumedix Announces Exclusive Commercialization Agreement with ThioLogics...more
28/01/2016 Eleven Biotherapeutics and Albumedix Announce Agreement...more
19/01/2016 Novozymes separates its biopharma activities to form independent company...more
19/05/2015 Serendex Pharmaceuticals to initiate trials with Novozymes Biopharma stabilizer...more
22/12/2014 Novozymes Biopharma enters license agreement with EpiVax...more
11/12/2014 Novozymes Biopharma published in Expert Opinion on Drug Delivery...more
05/11/2014 Novozymes Biopharma signs Chinese distribution agreement ...more
29/05/2014 Novozymes Biopharma enters new research agreement with top vaccine company...more
12/05/2014 Novozymes Biopharma announces new collaboration with ThioLogics...more
24/04/2014 Novozymes’ half-life extension technology reaches landmark milestone...more
31/03/2014 Novozymes Biopharma technology used by GlaxoSmithKline in type 2 diabetes drug...more
13/03/2014 Novozymes Biopharma announces collaboration with Janssen...more
21/01/2014 Novozymes Biopharma announces new data on extending serum albumin half-life...more
23/10/2013 Novozymes Biopharma announces collaboration with Almac ...more
18/07/2013 Novozymes Biopharma announce new findings concerning the effect of Hyaluronic Acid...more
29/05/2013 Novozymes Biopharma to showcase world leading products at CPhI China...more
20/05/2013 Novozymes Biopharma helps innovative dry eye therapy move into clinical trials...more
27/02/2013 Novozymes Biopharma's rAlbumin approved in Japan...more
13/02/2013 Novozymes Biopharma announces research agreement with EpiVax...more
21/12/2012 Novozymes aligns recombinant human albumin portfolio with new brand name...more
18/05/2012 Novozymes Biopharma Innovation 2012 award win...more
09/05/2012 Novozymes starts commercial supply of hyaluronic acid from Q7 cGMP facility...more
02/05/2012 Novozymes´ rAlbumin supports faster time to market for Neomend product...more